Capital Fund Management (CFM)
ADVM

Capital Fund Management (CFM)’s Adverum Biotechnologies ADVM Stock Holding History

Capital Fund Management (CFM)’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,273
Closed -$377K – 1515
2019
Q4 		$377K Buy
+3,273
New +$288K ﹤0.01% 1511

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Capital Fund Management (CFM)'s ADVM Position: Q1 2020 in Review

Capital Fund Management (CFM) sold out of Adverum Biotechnologies (ADVM) in Q1 2020, closing a stake of 3,273 shares — an estimated $377K sold.

Capital Fund Management (CFM) first reported a position in ADVM in Q4 2019 and held it in 1 quarter. The position peaked at $377K in Q4 2019. 126 funds tracked by Wall St. Rank hold ADVM as of Q1 2020.

  • Capital Fund Management (CFM) reported no remaining Adverum Biotechnologies position as of Q1 2020 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 3,273 Adverum Biotechnologies shares in Q1 2020, an estimated $377K.
  • Capital Fund Management (CFM) first reported a position in Adverum Biotechnologies in Q4 2019 and held it in 1 quarter.
  • Capital Fund Management (CFM)'s Adverum Biotechnologies position peaked at $377K in Q4 2019.
  • 126 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2020.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2020, filed 13 May 2020.